Galectin Therapeutics
GALT
60 hedge funds and large institutions have $12M invested in Galectin Therapeutics in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 15 increasing their positions, 16 reducing their positions, and 4 closing their positions.
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
64% more call options, than puts
Call options by funds: $450K | Put options by funds: $275K
9% more funds holding
Funds holding: 55 → 60 (+5)
0.24% more ownership
Funds ownership: 12.35% → 12.58% (+0.24%)
6% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 16
21% less capital invested
Capital invested by funds: $15.2M → $12M (-$3.14M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
STA
Summit Trail Advisors
New York
|
+$46.2K |
| 2 |
CF
Centaurus Financial
Anaheim,
California
|
+$40.9K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$35.6K |
| 4 |
Wolverine Trading
Chicago,
Illinois
|
+$31.7K |
| 5 |
State Street
Boston,
Massachusetts
|
+$29K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$172K |
| 2 |
Millennium Management
New York
|
-$131K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$84K |
| 4 |
Morgan Stanley
New York
|
-$57.7K |
| 5 |
JF
Jump Financial
Chicago,
Illinois
|
-$48K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
51
Tower Research Capital (TRC)
New York
| $4K | -$13.4K | -6,940 | -74% |
|
52
Fidelity Investments
Boston,
Massachusetts
| $3K | +$3.83K | +1,980 | +4,400% |
|
|
BCPWM
53
Bradley & Co Private Wealth Management
Miami,
Florida
| $2K | – | – | – |
|
|
MCC
54
Money Concepts Capital
Palm Beach Gardens,
Florida
| $2K | +$1.94K | +1,000 | New |
|
|
APA
55
American Portfolios Advisors
Holbrook,
New York
| $1.66K | – | – | – |
|
|
AWM
56
Accel Wealth Management
Waverly,
Iowa
| $1K | – | – | – |
|
57
BNP Paribas Financial Markets
Paris,
France
| $21 | – | – | – |
|
|
58
Citadel Advisors
Miami,
Florida
| – | -$84K | -43,382 | Closed |
|
|
JF
59
Jump Financial
Chicago,
Illinois
| – | -$48K | -23,200 | Closed |
|
60
Squarepoint
New York
| – | -$27K | -13,182 | Closed |
|
|
CA
61
CoreCap Advisors
Southfield,
Michigan
| – | -$19K | -9,195 | Closed |
|
|
GRP
62
Global Retirement Partners
San Rafael,
California
| – | +$677 | +350 | New |
|
GALT Hedge Fund Activity: Q1 2022 in Review
60 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q1 2022, worth a combined $12M — down 21% from $15.2M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new GALT positions and 4 closed out — a net gain of 5 holders — while 15 added to existing stakes and 16 trimmed.
The largest buyer was Summit Trail Advisors, opening a new position worth an estimated $46.2K. The largest seller was Susquehanna International Group, cutting an estimated $172K.
- 60 institutional investors held Galectin Therapeutics (GALT) as of Q1 2022, up from 55 in Q4 2021.
- Funds reported $12M of Galectin Therapeutics stock for Q1 2022, down 21% quarter-over-quarter.
- 9 funds opened new Galectin Therapeutics positions in Q1 2022 and 4 closed out, a net change of +5 holders.
- The largest Galectin Therapeutics buyer in Q1 2022 was Summit Trail Advisors, an estimated $46.2K added.
- The largest Galectin Therapeutics seller in Q1 2022 was Susquehanna International Group, an estimated $172K sold.
Based on aggregated 13F filings for Q1 2022.